Verona Pharma plc
VRNA
株式のランク
#2200
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
株価
$106.91
最終同期: 2025-10-07
時価総額
$9.09B
変化（1日）
0.00%
変化（1年）
0.00%
国
GB
取引 Verona Pharma plc (VRNA)
カテゴリー
Healthcare
Verona Pharma plc（VRNA）の株価履歴
終値の最高値: $106.85 （2025-10-01）
終値の最安値: $13.50 （2017-04-01）
終値の最安値: $13.50 （2017-04-01）
Verona Pharma plc の株価履歴（2017 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2025 | 154.19% |
| 2024 | 157.60% |
| 2023 | -2.67% |
| 2022 | 215.71% |
| 2021 | -30.29% |
| 2020 | 68.43% |
| 2019 | -55.34% |
| 2018 | -13.21% |
| 2017 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.89 | -3.74% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
